Biosensors has announced a distribution agreement with Veryan Medical for BioMimics 3D, a nitinol stent with three-dimensional helical geometry designed for use in the superficial femoral artery. The agreement covers certain international markets, but excludes the USA and Japan.
Medtronic has revealed new one-year clinical data showing that transcatheter aortic valve replacement (TAVR) with the self-expanding CoreValve System offers advantages in survival and safety compared to surgical aortic valve replacement (SAVR) in high risk aortic stenosis patients who have previously undergone coronary artery bypass grafting (CABG) surgery. This is the first analysis to evaluate a self-expanding valve in prior-CABG patients within a trial of TAVR and SAVR.
The National Institute for Health and Care Excellence (NICE) today issued its Final Appraisal Determination (FAD) recommending Xarelto 2.5mg twice daily as an effective treatment option for preventing secondary events, such as death, heart attack or stroke, following acute coronary syndrome in patients with elevated cardiac biomarkers, without prior stroke or transient ischaemic attack.
Transcatheter Technologies GmbH has expanded the Trinity technology platform to include a transfemoral version.
NuVascular Technologies has obtained exclusive licensing rights to commercialise a breakthrough medical device that will provide a minimally invasive treatment for heart disease, which accounts for one in every four deaths in the USA.
Micro Interventional Devices (MID) has completed enrolment in its secure transapical access and closure study (STASIS). STASIS is a non-randomised, multicentre, CE mark study, evaluating the safety and performance of Permaseal, an automated direct myocardial ventricular access and closure technology especially designed for use in transcatheter valve replacement procedures (TAVR and TMVR).
A study of portable ultrasound carried out in the USA, Canada and India has revealed the potential of this technology for detecting plaques in peripheral arteries that can lead to heart attacks and stroke before symptoms arise, in both developed and developing country settings, allowing preventive treatment in those affected.
Gerhard Schymik (Medical Clinic IV-Municipal Hospital Karlsruhe, Karlsruhe, Germany) and others report in Circulation: Cardiovascular Interventions that at a centre with an experienced multidisciplinary heart team, transapical transcatheter aortic valve implantation (TAVI) can be performed with comparable results to transfemoral TAVI.
Sorin has received US Food and Drug Administration (FDA) clearance for Memo 3D ReChord, an innovative semi-rigid annuloplasty ring for mitral valve repair.
A Henry Ford Hospital cardiologist helped perform the first successful transcaval valve replacement in Europe, sharing his expertise on a pioneering way to access the heart.
Cardio3 BioSciences has announced the enrolment of the 240th patient in its CHART-1 European trial for C-Cure, the first and only stem cell therapeutic using guided stem cells for the treatment of congestive heart failure.
Boulle Medtech has announced that the Tendyne transcatheter mitral valve implant was successfully placed in the first patient enrolled in a three-continent, multicentre trial being conducted as part of the Tendyne feasibility study. The study is to generate insight into the safety and performance of the Tendyne device in inoperable patients suffering from mitral regurgitation.
NEW YORK, March 16, 2015 /PRNewswire-USNewswire/ -- Newer drug-coated stents that keep arteries open have similar long-term rates of death compared with traditional bypass surgery for patients with more than one diseased coronary artery.
Horst Sievert, CardioVascular Center, Frankfurt, Germany reported “interesting, but inconclusive observations” from a small cohort of patients enrolled in the RETREAT (Renal denervation with ultrasound after failed radiofrequency denervation) study.
Boston Scientific has initiated full commercial launch of the new Polaris imaging system. This system will support the Boston Scientific family of intravascular ultrasound (IVUS) catheters, including coronary, peripheral and intra-cardiac echo products. The Polaris imaging system offers enhanced ease-of-use and more powerful processing capabilities. Its modular design would also support the planned release of new Boston Scientific imaging products including a fractional flow reserve (FFR) wire, a new family of IVUS catheters, enhanced software features and better system control tools.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos